KRX Bio Technology Transfer Index

Final data from the Phase 1b clinical trial of APB-A1 in thyroid eye disease (TED) is scheduled to be presented at the ENDO 2026 conference starting June 13, 2026. High importance is estimated as clinical trial results typically drive significant price volatility in the biotech sector, scheduled

1Q 2026 earnings release is scheduled. Analysts forecast strong performance driven by K-CAB sales in domestic and Chinese markets, with revenues of approx. KRW 260-264 billion and operating profit of approx. KRW 28-30 billion forecasted.

Yuhan's partner Johnson & Johnson is expected to announce on 2026-04-15 that 1Q 2026 sales of the Leclaza and Rybrevant combination therapy reached $257 million, an 82% year-over-year increase; this strong growth in a key revenue driver is likely to have a significant market impact, expected.

On April 15, 2026, Hanmi initiated procedures for a global Phase 2 clinical trial for 'HM15275', with the trial scheduled to begin in May 2026 scheduled.

Analysts forecast that Yuhan's 1Q 2026 earnings will be below market consensus due to a delayed milestone payment for Leclaza's European approval; the impact is expected to be limited as it is a timing issue, forecasted.

Analysts forecast that Q1 2026 earnings will likely be below market consensus due to a high base effect and sluggish sales in China, estimated.

Analysts forecast that Q1 2026 earnings will meet market expectations, driven by sales of the obesity treatment Wegovy, though R&D momentum may slow in the short term, forecasted.

Yuhan's new drug candidate for Gaucher disease, 'YH35995', is expected to receive Orphan Drug Designation (ODD) from the U.S. FDA on 2026-04-13; this regulatory milestone is likely to moderately boost investor confidence, expected.

The company announced it filed a Phase 3 IND application for 'Fexuclue' to treat gastric ulcers; analysts estimate a 1-5% price impact due to clinical progress scheduled.

The company paid an annual dividend of KRW 500 per share on April 10, 2026.

Special related parties of the largest shareholder gifted a total of 4,000 shares on 2026-04-10, as disclosed on April 15, 2026.